Pharsight

Nexiclon Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8337890 ATHENA Modified release formulations containing drug-ion exchange resin complexes
Apr, 2027

(2 years from now)

US8623409 ATHENA Clonidine formulation
Sep, 2031

(7 years from now)

Nexiclon Xr is owned by Athena.

Nexiclon Xr contains Clonidine.

Nexiclon Xr has a total of 2 drug patents out of which 0 drug patents have expired.

Nexiclon Xr was authorised for market use on 03 December, 2009.

Nexiclon Xr is available in tablet, extended release;oral dosage forms.

The generics of Nexiclon Xr are possible to be released after 08 September, 2031.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using CLONIDINE ingredient

Market Authorisation Date:

03 December, 2009

Treatment:

NA

Dosage:

TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

NEXICLON XR family patents

Family Patents